ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started
ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.
Stocks · News reference
Cantor Fitzgerald Maintains Neutral Rating on ADMA Biologics and Raises Price Target
Cantor Fitzgerald has updated its outlook on ADMA Biologics, maintaining a Neutral rating while increasing the price target to $13 from $12.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ADMA Biologics Reports Third Quarter 2026 Financial Results
ADMA Biologics, Inc. announced its financial results for the third quarter of 2026, reporting adjusted earnings per share of $0.23 and revenue of $141.1 million.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
8-K filing — ADMA BIOLOGICS, INC. (ADMA)
Filed: 2026-11-04 AccNo: 0001140361-26-041959 Size: 547 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
ADMA Biologics, Inc. has scheduled the release of its third quarter 2026 financial results for November 4, 2026, following the close of U.S. financial markets.
ADMA Biologics shares are trading higher after the company announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the company’s optimized, proprietary intravenous immune globulin manufacturing process.